The co‐existence of POLE mutations and MMRd/MSI in EC 26, 38 and the variation in its prevalence by POLE mutation location raise important questions about which is the initial, presumably dominant factor determining tumour phenotype and clinical outcome. The gene discussed is POLE; the disease is neoplasm.